Immutep's Engagement with Investors at Major Conferences
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a leading name in late-stage immunotherapy, is gearing up to engage with investors in a series of noteworthy conferences. With a focus on innovative treatments for cancer and autoimmune conditions, Immutep's management team is set to present and partake in one-on-one sessions at these events.
Upcoming Conference Schedule
Jones Healthcare and Technology Innovation Conference
Immutep will showcase its advancements at the Jones Healthcare and Technology Innovation Conference. Attendees can expect insights into Immutep's pioneering work scheduled for April 9, 2025, at 4:30 pm ET in Las Vegas, Nevada. This conference serves as a perfect platform for the company to highlight its achievements and plans.
The Citizens Life Sciences Conference
This prestigious gathering will take place on May 8, 2025, at 1:00 pm ET in New York. During this conference, Immutep aims to deepen connections with investors and share progress on its immunotherapeutic developments. The team is enthusiastic about exchanging ideas and showcasing their strategic pathways.
Jefferies Global Healthcare Conference
Adding to a busy calendar, Immutep is scheduled to participate in the Jefferies Global Healthcare Conference on June 4 and 5, 2025, also in New York. Here, the company will provide updates on their innovative treatment options and engage with the broader healthcare investment community.
Insights on Immutep's Mission
Immutep stands at the forefront of biotechnology, with a strong commitment to developing cutting-edge immunotherapies. The company has made significant strides in the understanding of Lymphocyte Activation Gene-3 (LAG-3), allowing for tailored treatment options that modulate the immune response effectively. Through its extensive product portfolio, Immutep is dedicated to providing patients with novel therapies that can change the landscape of treatment for challenging conditions.
Company Contact Information
For Australian Investors and Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com
For U.S. Media Inquiries:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
Frequently Asked Questions
What is Immutep Limited known for?
Immutep Limited is known for its development of advanced immunotherapies aimed at treating cancer and autoimmune diseases.
When and where are the upcoming investor conferences?
The upcoming conferences are the Jones Healthcare and Technology Innovation Conference on April 9, 2025, in Las Vegas, the Citizens Life Sciences Conference on May 8, 2025, in New York, and the Jefferies Global Healthcare Conference on June 4-5, 2025, also in New York.
What is LAG-3?
LAG-3 is a protein that plays a crucial role in downregulating immune responses. Immutep focuses on leveraging this to develop therapies that can help patients with autoimmune diseases and cancer.
How can investors connect with Immutep?
Investors can engage with Immutep during the upcoming conferences or reach out through provided contact information for any inquiries.
Where can I find more information about Immutep?
More information can be obtained from Immutep's website, where they regularly update details about their pipeline and conferences.
